Metabolomics of human breast cancer

New approaches for tumor typing and biomarker discovery

C. Denkert (Corresponding Author), Elmar Bucher, Mika Hilvo, Reza Salek, Matej Orešič, J. Griffin, S. Brockmöller, F. Klauschen, S. Loibl, D. K. Barubal, J. Budczies, Kristiina Iljin, V. Nekljudova, O. Fiehn

Research output: Contribution to journalReview ArticleScientificpeer-review

66 Citations (Scopus)

Abstract

Breast cancer is the most common cancer in women worldwide, and the development of new technologies for better understanding of the molecular changes involved in breast cancer progression is essential. Metabolic changes precede overt phenotypic changes, because cellular regulation ultimately affects the use of small-molecule substrates for cell division, growth or environmental changes such as hypoxia. Differences in metabolism between normal cells and cancer cells have been identified. Because small alterations in enzyme concentrations or activities can cause large changes in overall metabolite levels, the metabolome can be regarded as the amplified output of a biological system. The metabolome coverage in human breast cancer tissues can be maximized by combining different technologies for metabolic profiling. Researchers are investigating alterations in the steady state concentrations of metabolites that reflect amplified changes in genetic control of metabolism. Metabolomic results can be used to classify breast cancer on the basis of tumor biology, to identify new prognostic and predictive markers and to discover new targets for future therapeutic interventions. Here, we examine recent results, including those from the European FP7 project METAcancer consortium, that show that integrated metabolomic analyses can provide information on the stage, subtype and grade of breast tumors and give mechanistic insights. We predict an intensified use of metabolomic screens in clinical and preclinical studies focusing on the onset and progression of tumor development.
Original languageEnglish
Article number37
Number of pages9
JournalGenome Medicine
Volume4
Publication statusPublished - 2012
MoE publication typeA2 Review article in a scientific journal

Fingerprint

Metabolomics
Tumor Biomarkers
Breast Neoplasms
Metabolome
Neoplasms
Technology
Cell Division
Research Personnel
Enzymes
Growth

Keywords

  • breast cancer
  • metabolomics
  • lipidomics
  • biomarker analysis

Cite this

Denkert, C., Bucher, E., Hilvo, M., Salek, R., Orešič, M., Griffin, J., ... Fiehn, O. (2012). Metabolomics of human breast cancer: New approaches for tumor typing and biomarker discovery. Genome Medicine, 4, [37].
Denkert, C. ; Bucher, Elmar ; Hilvo, Mika ; Salek, Reza ; Orešič, Matej ; Griffin, J. ; Brockmöller, S. ; Klauschen, F. ; Loibl, S. ; Barubal, D. K. ; Budczies, J. ; Iljin, Kristiina ; Nekljudova, V. ; Fiehn, O. / Metabolomics of human breast cancer : New approaches for tumor typing and biomarker discovery. In: Genome Medicine. 2012 ; Vol. 4.
@article{a2d44d48a83c45d197bf2c246ce9ecb4,
title = "Metabolomics of human breast cancer: New approaches for tumor typing and biomarker discovery",
abstract = "Breast cancer is the most common cancer in women worldwide, and the development of new technologies for better understanding of the molecular changes involved in breast cancer progression is essential. Metabolic changes precede overt phenotypic changes, because cellular regulation ultimately affects the use of small-molecule substrates for cell division, growth or environmental changes such as hypoxia. Differences in metabolism between normal cells and cancer cells have been identified. Because small alterations in enzyme concentrations or activities can cause large changes in overall metabolite levels, the metabolome can be regarded as the amplified output of a biological system. The metabolome coverage in human breast cancer tissues can be maximized by combining different technologies for metabolic profiling. Researchers are investigating alterations in the steady state concentrations of metabolites that reflect amplified changes in genetic control of metabolism. Metabolomic results can be used to classify breast cancer on the basis of tumor biology, to identify new prognostic and predictive markers and to discover new targets for future therapeutic interventions. Here, we examine recent results, including those from the European FP7 project METAcancer consortium, that show that integrated metabolomic analyses can provide information on the stage, subtype and grade of breast tumors and give mechanistic insights. We predict an intensified use of metabolomic screens in clinical and preclinical studies focusing on the onset and progression of tumor development.",
keywords = "breast cancer, metabolomics, lipidomics, biomarker analysis",
author = "C. Denkert and Elmar Bucher and Mika Hilvo and Reza Salek and Matej Orešič and J. Griffin and S. Brockm{\"o}ller and F. Klauschen and S. Loibl and Barubal, {D. K.} and J. Budczies and Kristiina Iljin and V. Nekljudova and O. Fiehn",
year = "2012",
language = "English",
volume = "4",
journal = "Genome Medicine",
issn = "1756-994X",

}

Denkert, C, Bucher, E, Hilvo, M, Salek, R, Orešič, M, Griffin, J, Brockmöller, S, Klauschen, F, Loibl, S, Barubal, DK, Budczies, J, Iljin, K, Nekljudova, V & Fiehn, O 2012, 'Metabolomics of human breast cancer: New approaches for tumor typing and biomarker discovery', Genome Medicine, vol. 4, 37.

Metabolomics of human breast cancer : New approaches for tumor typing and biomarker discovery. / Denkert, C. (Corresponding Author); Bucher, Elmar; Hilvo, Mika; Salek, Reza; Orešič, Matej; Griffin, J.; Brockmöller, S.; Klauschen, F.; Loibl, S.; Barubal, D. K.; Budczies, J.; Iljin, Kristiina; Nekljudova, V.; Fiehn, O.

In: Genome Medicine, Vol. 4, 37, 2012.

Research output: Contribution to journalReview ArticleScientificpeer-review

TY - JOUR

T1 - Metabolomics of human breast cancer

T2 - New approaches for tumor typing and biomarker discovery

AU - Denkert, C.

AU - Bucher, Elmar

AU - Hilvo, Mika

AU - Salek, Reza

AU - Orešič, Matej

AU - Griffin, J.

AU - Brockmöller, S.

AU - Klauschen, F.

AU - Loibl, S.

AU - Barubal, D. K.

AU - Budczies, J.

AU - Iljin, Kristiina

AU - Nekljudova, V.

AU - Fiehn, O.

PY - 2012

Y1 - 2012

N2 - Breast cancer is the most common cancer in women worldwide, and the development of new technologies for better understanding of the molecular changes involved in breast cancer progression is essential. Metabolic changes precede overt phenotypic changes, because cellular regulation ultimately affects the use of small-molecule substrates for cell division, growth or environmental changes such as hypoxia. Differences in metabolism between normal cells and cancer cells have been identified. Because small alterations in enzyme concentrations or activities can cause large changes in overall metabolite levels, the metabolome can be regarded as the amplified output of a biological system. The metabolome coverage in human breast cancer tissues can be maximized by combining different technologies for metabolic profiling. Researchers are investigating alterations in the steady state concentrations of metabolites that reflect amplified changes in genetic control of metabolism. Metabolomic results can be used to classify breast cancer on the basis of tumor biology, to identify new prognostic and predictive markers and to discover new targets for future therapeutic interventions. Here, we examine recent results, including those from the European FP7 project METAcancer consortium, that show that integrated metabolomic analyses can provide information on the stage, subtype and grade of breast tumors and give mechanistic insights. We predict an intensified use of metabolomic screens in clinical and preclinical studies focusing on the onset and progression of tumor development.

AB - Breast cancer is the most common cancer in women worldwide, and the development of new technologies for better understanding of the molecular changes involved in breast cancer progression is essential. Metabolic changes precede overt phenotypic changes, because cellular regulation ultimately affects the use of small-molecule substrates for cell division, growth or environmental changes such as hypoxia. Differences in metabolism between normal cells and cancer cells have been identified. Because small alterations in enzyme concentrations or activities can cause large changes in overall metabolite levels, the metabolome can be regarded as the amplified output of a biological system. The metabolome coverage in human breast cancer tissues can be maximized by combining different technologies for metabolic profiling. Researchers are investigating alterations in the steady state concentrations of metabolites that reflect amplified changes in genetic control of metabolism. Metabolomic results can be used to classify breast cancer on the basis of tumor biology, to identify new prognostic and predictive markers and to discover new targets for future therapeutic interventions. Here, we examine recent results, including those from the European FP7 project METAcancer consortium, that show that integrated metabolomic analyses can provide information on the stage, subtype and grade of breast tumors and give mechanistic insights. We predict an intensified use of metabolomic screens in clinical and preclinical studies focusing on the onset and progression of tumor development.

KW - breast cancer

KW - metabolomics

KW - lipidomics

KW - biomarker analysis

M3 - Review Article

VL - 4

JO - Genome Medicine

JF - Genome Medicine

SN - 1756-994X

M1 - 37

ER -

Denkert C, Bucher E, Hilvo M, Salek R, Orešič M, Griffin J et al. Metabolomics of human breast cancer: New approaches for tumor typing and biomarker discovery. Genome Medicine. 2012;4. 37.